Effects of berberine on lipid profile in subjects with low cardiovascular risk

Expert Opinion on Biological Therapy

Volumn 13, Issue 4, 2013, Pages 475-482

  Derosa, Giuseppe ^a   D'Angelo, Angela ^a   Bonaventura, Aldo ^a   Bianchi, Lucio ^a   Romano, Davide ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Berberine; Cardiovascular risk; Diet; Lipid profile; Physical activity

Indexed keywords

BERBERINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MYOPATHY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PILOT STUDY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; BERBERINE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84878729536     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.776037     Document Type: Article

References (40)

1. Muller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J 2008;29:1316-26
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97
3. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
4. Gotto AM Jr. Treating hypercholesterolemia: looking forward. Clin Cardiol 2003;26(1):21-8
5. Buller N, Gillen D, Casciano R, et al. A pharmacoeconomic evaluation of the myocardial ischaemia reduction with aggressive cholesterol lowering (MIRACL) study in the United Kingdom. Pharmacoeconomics 2003;21(1):25-32
6. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol lowering therapies according to patient characteristics. Ann Intern Med 2000;132:769-79
7. Pearson TA, Bazzarre TL, Daniels SR, et al. American Heart Association Expert Panel on Population and Prevention Science. American heart association guide for improving cardiovascular health at the community level. A statement for public health practitioners, healthcare providers, and health policy makers from the American heart association expert panel on population and prevention science. Circulation 2003;107:645-51
8. Cicero AFG, Derosa G, Bove M, et al. A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. Mediterr J Nutr Metab 2008;1:33-6
9. Cicero AFG, Derosa G, Bove M, et al. Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. Curr Top Nutraceut R 2009;7(3/4):121-6
10. Cicero AF, Derosa G, Di Gregori V, et al. Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. Clin Exp Hypertens 2010;32(2):137-44
11. Derosa G, Cicero AFG, Fogari E, et al. Effects of n-3 PUFAs on insulin resistance after an oral fat load. Eur J Lipid Sci Technol 2011;113(8):950-60
12. Derosa G, Cicero AFG, Fogari E, et al. n-3 PUFAs effects on post-prandial variation of metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol 2012;6(6):553-64
13. Cicero AFG, Derosa G, Bove M, et al. Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. Mediterr J Nutr Metab 2010;3:47-54
14. Cicero AF, Derosa G, Miconi A, et al. Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10? Biofactors 2005;23(1):7-14
15. Derosa G, Cicero AFG, Gaddi A, et al. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003;25(5):1429-39
16. Derosa G, Maffioli P, Ferrari I, et al. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J 2010;57(9):777-86
17. Derosa G, Maffioli P, Salvadeo SA, et al. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med 2010;49(16):1717-25
18. Derosa G, Maffioli P, Ferrari I, et al. Comparison between orlistat plus L-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol 2011;25(5):642-51
19. Derosa G, Maffioli P, Salvadeo SA, et al. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism 2011;60(3):421-9
20. Cicero AFG, Derosa G. Rice bran and its main components: potential role in the management of coronary risk factors. Curr Top Nutraceut R 2005;3(1):29-46
21. Cicero AF, Derosa G, Borghi C. Red yeast rice and statin-intolerant patients. Am J Cardiol 2010;105(10):1504
22. Caron MF, White CM. Evaluation of the antihyperlipidemic properties of dietary supplements. Pharmacotherapy 2001;21(4):481-7
23. Ferrari CK. Functional foods, herbs and nutraceuticals: towards biochemical mechanisms of healthy aging. Biogerontology 2004;5(5):275-89
24. Birdsall TC, Kelly GS. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev 1997;2:94-103
25. Derosa G, Maffioli P, Cicero AFG. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012;12(8):1113-24
26. Proposed International Guidelines for Biomedical Research Involving Human Subjects. The Council for International Organisation of Medical Sciences. CIOMS, Geneva; 1982
27. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO consultation on obesity. WHO, Geneva; 1997
28. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines subcommittee. J Hypertens 1999;17:151-83
29. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30
30. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. J Clin Chem Clin Biochem 1978;15:121-30
31. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bergmeyer HU, editor. Methods of enzymatic analysis. 2nd English edition. Academic Press, New York (USA); 1974. p. 18-31
32. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
34. Winer BJ. Statistical principles in experimental design. 2nd edition. McGraw-Hill, New York (USA); 1971
35. Stys T, Stys A, Kelly P, Lawson W. Trends in use of herbal and nutritional supplements in cardiovascular patients. Clin Cardiol 2004;27(2):87-90
36. Cicero AFG, Derosa G, Gaddi A. What herbalists suggest to our diabetic patients in order to improve their glycaemic control? Evaluation of scientific evidences and potential risks. Acta Diabetol 2004;41(3):91-8
37. Affuso F, Ruvolo A, Micillo F, et al. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 2010;20:656-61
38. Affuso F, Mercurio V, Ruvolo A, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol 2012;4:77-83
39. Liu L, Yu YL, Yang JS, et al. Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol 2010;381:371-81
40. Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care. Br J Gen Pract 2003;53(494):684-9